Ilsung Pharmaceuticals Co., Ltd.

KSE 003120.KS

Ilsung Pharmaceuticals Co., Ltd. Operating Cash Flow for the year ending December 31, 2023: USD -31.85 M

Ilsung Pharmaceuticals Co., Ltd. Operating Cash Flow is USD -31.85 M for the year ending December 31, 2023, a -3.47% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Ilsung Pharmaceuticals Co., Ltd. Operating Cash Flow for the year ending December 31, 2022 was USD -30.78 M, a -744.77% change year over year.
Ilsung Pharmaceuticals Co., Ltd. Operating Cash Flow for the year ending December 31, 2021 was USD 4.77 M, a 233.96% change year over year.
Ilsung Pharmaceuticals Co., Ltd. Operating Cash Flow for the year ending December 31, 2020 was USD 1.43 M, a -62.21% change year over year.
Ilsung Pharmaceuticals Co., Ltd. Operating Cash Flow for the year ending December 31, 2019 was USD 3.78 M, a -71.96% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

KSE: 003120.KS

Ilsung Pharmaceuticals Co., Ltd.

CEO	Mr. Seok-geun Yoon
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	84-gil 9, Wonhyo-ro
Employees	224
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food Plastics

Description

Ilsung Pharmaceuticals Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, anti-coagulants, circulatory system drugs, contrast agents, diabetes treatments, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, anesthetics, antipyretics, and cardiovascular system products. Ilsung Pharmaceuticals Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years